Zobrazeno 1 - 10
of 213
pro vyhledávání: '"Ruby F, Meredith"'
Autor:
Ruby F. Meredith, MD, PhD, John R. Bassler, MS, Andrew M. McDonald, MD, John M. Stahl, MD, David T. Redden, PhD, James A. Bonner, MD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 4, Pp 101214- (2023)
Purpose: Various radiation therapy (RT) dose/fractionation schedules are acceptable for palliation in multiple myeloma. Nine years of single-institution RT experience were reviewed to determine the influence of dose/fractionation and other factors pe
Externí odkaz:
https://doaj.org/article/62b9e9395c554974a6385a9fb2c0d0fc
Autor:
John B. Fiveash, MD, Waleed O. Arafat, MD, PhD, George E. Naoum, MD, Barton L. Guthrie, MD, Stephen M. Sawrie, MD, Sharon A. Spencer, MD, Ruby F. Meredith, MD, PhD, James M. Markert, MD, PhD, Robert M. Conry, MD, Burt L. Nabors, MD
Publikováno v:
Advances in Radiation Oncology, Vol 1, Iss 2, Pp 83-88 (2016)
Purpose: To determine if temozolomide reduces the risk of distant brain failure (DBF, metachronous brain metastases) in patients with 1 to 4 brain metastases treated with radiosurgery without whole-brain radiation therapy (WBRT). Methods and material
Externí odkaz:
https://doaj.org/article/3138cb00bd2b469ca97829cebaf9ba8b
Autor:
Ruby F. Meredith, Lawrence S. Lamb, Ayman Saad, Omer Jamy, Donna Salzman, Luciano J. Costa, Kentaro Minagawa, Susan Bal, Raquel Innis-Shelton, Shin Mineishi, Antonio Di Stasi, Ravi Kumar Paluri
Publikováno v:
American Journal of Hematology. 96
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47c56b8b845d5c6aa1b0f82510de0a5e
https://doi.org/10.1002/ajh.26296
https://doi.org/10.1002/ajh.26296
Autor:
Ayman Saad, Shin Mineishi, Joseph H. Chewning, Samantha Langford, Rivvi Kukkamalla, Donna Salzman, Rehan Sarmad, Ruby F. Meredith, Alankrita Taneja, Racquel Innis-Shelton, Ravi Bhatia, Vera Hauptfeld, Kirby Ann Plessala, Luciano J. Costa, Antonio Di Stasi, Lawrence S. Lamb
Publikováno v:
Bone Marrow Transplantation. 53:1345-1348
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1f6e698f009b4563680dfeb18c66aec
https://doi.org/10.1038/s41409-018-0185-6
https://doi.org/10.1038/s41409-018-0185-6
Autor:
J. Michael Straughn, Ronald D. Alvarez, Tania A. Rozgaja, E. Banaga, Julien Torgue, Michael C. Dobelbower, Ruby F. Meredith, Andrew M. Lowy, Patty Bunch
Publikováno v:
American Journal of Clinical Oncology
One-year monitoring of patients receiving intraperitoneal (IP) 212Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. Eighteen patients with relapsed intra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2180d3d5c2576ea420552ca744cce370
http://europepmc.org/articles/PMC5449266
http://europepmc.org/articles/PMC5449266
Autor:
James M. Markert, Barton L. Guthrie, John B. Fiveash, Ruby F. Meredith, Robert M. Conry, Sharon A. Spencer, Stephen M. Sawrie, Burt Nabors, George E. Naoum, Waleed Arafat
Publikováno v:
Advances in Radiation Oncology
Advances in Radiation Oncology, Vol 1, Iss 2, Pp 83-88 (2016)
Advances in Radiation Oncology, Vol 1, Iss 2, Pp 83-88 (2016)
Purpose To determine if temozolomide reduces the risk of distant brain failure (DBF, metachronous brain metastases) in patients with 1 to 4 brain metastases treated with radiosurgery without whole-brain radiation therapy (WBRT). Methods and materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96c1c8fee186081d5aa2f131f169b587
Autor:
Darrell R. Fisher, Sui Shen, Ruby F. Meredith, E. Banaga, Desiree E. Morgan, J. Michael Straughn, Patty Bunch, Jinda Fan, Julien Torgue
Publikováno v:
Journal of Nuclear Medicine. 55:1636-1642
Our purpose was to study the safety, distribution, pharmacokinetics, immunogenicity, and tumor response of intraperitoneal 212Pb-TCMC-trastuzumab (TCMC is S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra(2-carbamoylmethyl)cyclododecane)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d9a1331ae833325dd253b41fb43ba2
https://doi.org/10.2967/jnumed.114.143842
https://doi.org/10.2967/jnumed.114.143842
Autor:
Susan J. Knox, Andres Forero-Torres, Jatin J. Shah, Albert F. LoBuglio, Ivana N. Micallef, Sui Shen, Ruby F. Meredith, Christos Vaklavas
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 28:370-379
Radioimmunotherapy capitalizes on the radiosensitivity of non-Hodgkin lymphoma (NHL) and the targeted nature of monoclonal antibodies. In an attempt to reverse bone marrow infiltration with B-cells and optimize the biodistribution of Yttrium-90 (90Y)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e095b45e28e51ccf274e1c39383e9ae2
https://doi.org/10.1089/cbr.2012.1387
https://doi.org/10.1089/cbr.2012.1387
Autor:
Dorothy A. Shead, Ruby F. Meredith, Keith Stockerl-Goldstein, Amrita Krishnan, Benjamin Djulbegovic, Kenneth C. Anderson, Seema Singhal, Joachim Yahalom, Adam D. Cohen, Jeffrey Schriber, Michael Liedtke, William I. Bensinger, Carol Ann Huff, Furhan Yunus, Francisco J. Hernandez-Illizaliturri, Rashmi Kumar, Adetola A. Kassim, J. Sybil Biermann, Cristina Gasparetto, Donna M. Weber, Noopur Raje, Steven M. Devine, Edward A. Faber, George Somlo, Steven P. Treon, Melissa Alsina
Publikováno v:
Journal of the National Comprehensive Cancer Network. 11:11-17
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::128cd17c70113ba33d6ea1035b12ef36
https://doi.org/10.6004/jnccn.2013.0004
https://doi.org/10.6004/jnccn.2013.0004
Autor:
Carla I. Falkson, John T. Carpenter, Brendan M. Prendergast, Ruby F. Meredith, K.S. Keene, Marshall M. Urist, Z You, J.F. De Los Santos, Kirby I. Bland, O.C. Barrett, Helen Krontiras, Andres Forero
Publikováno v:
Cancer Research. 72:P5-17
Background: Triple negative breast cancer (TNBC) comprises 15–20% of newly diagnosed invasive breast cancers and has been associated with an elevated risk of both local-regional recurrence (LRR) as well as distant failure. Bevacizumab (BEV) has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47e2624c24ef7adbfa2acdcac31c353b
https://doi.org/10.1158/0008-5472.sabcs12-p5-17-07
https://doi.org/10.1158/0008-5472.sabcs12-p5-17-07